1. The EGFR as a target for anticancer therapy-focus on Cetuximab;Baselga;Eur J of Cancer,2001
2. Continous administration of ZD1839 (Iressa®) a novel oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with 5 selected tumor types: evidence of activity and good tolerability;Baselga;Am J Clin Oncol,2000
3. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin;Baselga;J Clin Oncol,2000
4. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide;Bianco;Clin Cancer Res,2000
5. Phase II study of ZD1839 (Iressa®) in recurrent or metastatic squamous cell carcinoma of the head and neck;Cohen;Proc Am Soc Clin Oncol,2002